PMID- 29494961
OWN - NLM
STAT- MEDLINE
DCOM- 20180913
LR  - 20220408
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 101
DP  - 2018 May
TI  - Silymarin ameliorates expression of urotensin II (U-II) and its receptor (UTR) 
      and attenuates toxic oxidative stress in the heart of rats with type 2 diabetes.
PG  - 244-250
LID - S0753-3322(17)35989-9 [pii]
LID - 10.1016/j.biopha.2018.02.075 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is associated with an increased risk of 
      cardiovascular disease (CVD). Urotensin II ((U-II)) and its receptor (UTR) are 
      involved in the progression of CVD through enhancement in the production of 
      reactive oxygen species (ROS). Since silymarin (SMN) is a natural agent with 
      anti-diabetic effects, this study aimed to investigate the antioxidant potency of 
      SMN on the expression of (U-II)/UTR system and oxidative stress status in the 
      heart of type 2 diabetic rats. Thirty-six male Wistar rats were randomly divided 
      into six groups (n = 6). Control and diabetic groups treated with or without SMN 
      (60 and 120 mg/kg/day) for 2 months. Fasting blood sugar (FBS), insulin, lipid 
      profile, creatine kinase-MB ((CK-MB)), lactate dehydrogenase (LDH) and markers of 
      oxidative stress were measured by spectrophotometric methods while (U-II) and UTR 
      gene expression was determined by qPCR method. SMN significantly reduced the FBS 
      level, increased the concentration of insulin and improved HOMA-IR. SMN prevented 
      diabetes-induced weight loss, and attenuated the increased levels of total 
      oxidative status (TOS), malondialdehyde (MDA), and nitric oxide (NO). 
      Diabetes-induced reduction of total thiol molecules content (TTM) was normalized 
      to the normal level in SMN treated rats. SMN significantly modulated serum lipid 
      profile, reduced the expression of (U-II) and UTR in the heart, and improved 
      histopathological changes in the heart tissues. Therefore, the current study 
      indicated that SMN ameliorated unpleasant diabetic characteristics via 
      down-regulation of (U-II) and UTR gene expression and modulation of oxidative 
      stress in the heart tissue of type 2 diabetic rats.
CI  - Copyright (c) 2018 Elsevier Masson SAS. All rights reserved.
FAU - Rahimi, Rahimeh
AU  - Rahimi R
AD  - Department of Biochemistry, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
FAU - Karimi, Jamshid
AU  - Karimi J
AD  - Department of Biochemistry, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran. Electronic address: ja.karimi@umsha.ac.ir.
FAU - Khodadadi, Iraj
AU  - Khodadadi I
AD  - Department of Biochemistry, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
FAU - Tayebinia, Heidar
AU  - Tayebinia H
AD  - Department of Biochemistry, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
FAU - Kheiripour, Nejat
AU  - Kheiripour N
AD  - Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences, Kashan, Iran.
FAU - Hashemnia, Mohammad
AU  - Hashemnia M
AD  - Departments of Pathobiology, Veterinary Medicine Faculty, Razi University, 
      Kermanshah, Iran.
FAU - Goli, Fatemeh
AU  - Goli F
AD  - Department of Biochemistry, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
LA  - eng
PT  - Journal Article
DEP - 20180227
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antioxidants)
RN  - 0 (Lipids)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 0 (Silymarin)
RN  - 0 (Urotensins)
RN  - 0 (Uts2r protein, rat)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 9047-55-6 (urotensin II)
SB  - IM
MH  - Animals
MH  - Antioxidants/administration & dosage/pharmacology
MH  - Diabetes Mellitus, Experimental/complications/*drug therapy
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Heart/drug effects
MH  - Lipids/blood
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Nitric Oxide/metabolism
MH  - Oxidative Stress/drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Reactive Oxygen Species/metabolism
MH  - Receptors, G-Protein-Coupled/genetics
MH  - Silymarin/administration & dosage/*pharmacology
MH  - Urotensins/*genetics
OTO - NOTNLM
OT  - Heart
OT  - Silymarin
OT  - Type 2 diabetes mellitus
OT  - Urotensin II
OT  - Urotensin II receptor
EDAT- 2018/03/02 06:00
MHDA- 2018/09/14 06:00
CRDT- 2018/03/02 06:00
PHST- 2017/11/09 00:00 [received]
PHST- 2018/02/02 00:00 [revised]
PHST- 2018/02/19 00:00 [accepted]
PHST- 2018/03/02 06:00 [pubmed]
PHST- 2018/09/14 06:00 [medline]
PHST- 2018/03/02 06:00 [entrez]
AID - S0753-3322(17)35989-9 [pii]
AID - 10.1016/j.biopha.2018.02.075 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2018 May;101:244-250. doi: 10.1016/j.biopha.2018.02.075. 
      Epub 2018 Feb 27.